WO2002085424A1 - A coating for a stent and a method of forming the same - Google Patents

A coating for a stent and a method of forming the same Download PDF

Info

Publication number
WO2002085424A1
WO2002085424A1 PCT/US2002/011755 US0211755W WO02085424A1 WO 2002085424 A1 WO2002085424 A1 WO 2002085424A1 US 0211755 W US0211755 W US 0211755W WO 02085424 A1 WO02085424 A1 WO 02085424A1
Authority
WO
WIPO (PCT)
Prior art keywords
layer
stent
substance
forming
portions
Prior art date
Application number
PCT/US2002/011755
Other languages
French (fr)
Inventor
Syed F. A. Hossainy
Original Assignee
Advanced Cardiovascular Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Cardiovascular Systems, Inc. filed Critical Advanced Cardiovascular Systems, Inc.
Publication of WO2002085424A1 publication Critical patent/WO2002085424A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment

Definitions

  • the invention relates to implantable devices or endoluminal prostheses, such as stents. More particularly, this invention relates to a coating for a stent and methods for making the same.
  • Percutaneous transluminal coronary angioplasty is a procedure for treating heart disease.
  • a catheter assembly having a balloon portion is introduced percutaneo ⁇ sly into the cardiovascular system of a patient via the brachial or femoral artery.
  • the catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion.
  • the balloon is inflated to a predetermined size to radially press against the atherosclerotic plaque of the lesion for remodeling of the vessel wall.
  • the balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.
  • a problem associated with the above procedure includes formation of intimal flaps or torn arterial linings, which can collapse and occlude the conduit after the balloon is deflated. Nasospasms and recoil of the vessel wall also threaten vessel closure. Moreover, thrombosis and restenosis of the artery may develop over several months after the procedure, which may necessitate another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce the chance of the development of thrombosis and restenosis, an expandable, intraluminal prosthesis, one example of which is a stent, is implanted in the lumen to maintain the vascular patency.
  • Stents act as scaffoldings, functioning to physically hold open and, if desired, to expand the wall of the passageway.
  • stents are capable of being compressed, so that they can be inserted through small cavities via catheters, and then expanded to a larger diameter once they are at the desired location.
  • Examples in the patent literature disclosing stents that have been applied in PTCA procedures include U.S. Patent No. 4,733,665 issued to Palmaz, U.S. Patent No. 4,800,882 issued to Gianturco, and U.S. Patent No. 4,886,062 issued to Wiktor.
  • Mechanical intervention via stents has reduced the rate of restenosis as compared to balloon angioplasty.
  • restenosis is still a significant clinical problem with rates ranging from 20-40%.
  • its treatment can be challenging, as clinical options are more limited as compared to lesions that were treated solely with a balloon.
  • Stents are used not only for mechanical intervention but also as vehicles for providing biological therapy.
  • Biological therapy can be achieved by medicating the stents.
  • Medicated stents provide for the local administration of a therapeutic substance at the diseased site. In order to provide an efficacious concentration to the treated site,
  • This invention provides for a stent coating capable of sustained local delivery of therapeutic substances and methods of forming the coating.
  • a method of coating a stent includes forming a first layer supported by a stent substrate and patterning the first layer by removing portions of the first layer.
  • the method additionally includes forming a primer layer on the surface of the stent substrate prior to forming the first layer.
  • the method includes forming a second layer on the remaining portions of the first layer.
  • the first layer may contain a first substance and the second layer may contain a second substance different than the first substance.
  • the first and second substances may be active ingredients, radiopaque elements, or radioactive isotopes.
  • the act of patterning the first layer includes forming a second layer on the surface of the stent prior to forming the first layer.
  • the second layer is patterned to form vias in the second layer.
  • Such patterning may be performed by applying a laser discharge to selected areas of the second layer.
  • the first layer is formed on the remaining portions of the second layer and in the vias.
  • the second layer is patterned to remove portions of the first layer disposed on the remaining portion of the second layer to pattern the first layer.
  • the act of patterning the first layer includes forming a second layer on the surface of the stent prior to forming the first layer and patterning the second layer to expose portions of the surface of the stent.
  • the act of patterning the first layer also includes forming depots in the stent between the remaining portions of the second layer, wherein the first layer fills the depots, and removing the remaining portions of the second layer to remove portions of the first layer disposed on the remaining portions of the second layer, wherein the first layer remains in the depots.
  • a third layer may be formed on the surface of the stent and over the first layer in the depots.
  • the act of patterning the first layer includes forming a second layer on the first layer and patterning the second layer to form vias in the second layer to expose portions of the first layer.
  • the act of patterning the first layer also includes removing the exposed portions of the first layer, wherein portions of the first layer positioned underneath the remaining portions of the second layer remain essentially undisturbed, and removing the remaining portions of the second layer to form a patterned first layer.
  • a third layer may be formed on the remaining portions of the first layer.
  • a coated stent produced in accordance with the various methods is also provided.
  • the coated stent includes a first layer and a discontinuous second layer separated by the first layer.
  • the first layer is a discontinuous layer separated by the second layer so as to create an alternating pattern of the first and second layers on the surface of the stent.
  • the discontinuous first and second layers can be disposed on a primer layer.
  • Figure 1 illustrates a stent
  • Figures 2A-2G illustrate a method of coating a stent in accordance with . several embodiments of the invention.
  • Figures 3 A-3F illustrate a method of coating a stent in accordance with several other embodiments of the invention.
  • Figures 4A-4F illustrate a method of coating a stent in accordance with several other embodiments of the invention.
  • Figures 5A-5H illustrate a method of coating a stent in accordance with several other embodiments of the invention.
  • Polymer “poly,” and “polymeric” are defined as compounds that are the product of a polymerization reaction and are inclusive of homopolymers, copolymers, terpolymers etc., including random, alternating, block, and graft variations thereof.
  • EVOH ethylene vinyl alcohol copolymer
  • ENAL polyhydroxy alkanoates
  • PEO/PLA polyalkylene oxalates; polyphosphazenes and biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid; polyurethanes; silicones; polyesters; polyolefins; polyisobutylene and ethylene- alphaolefin copolymers; acrylic polymers and copolymers; vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics, such as polystyrene; polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene- methyl methacrylate copolymers, acryl
  • solvent is defined as a liquid substance or composition which is compatible with the polymer and is capable of dissolving the polymer at the concentration desired in the composition.
  • solvents include, but are not limited to, dimethylsulfoxide (DMSO), chloroform, acetone, water (buffered saline), xylene, methanol, ethanol, 1-propanol, tetrahydrofuran, 1-butanone, dimethylformamide, dimethylacetamide, cyclohexanone, ethyl acetate, methylethylketone, propylene glycol monomethylether, isopropanol, isopropanol admixed with water, N-methyl pyrrolidinone, toluene, and combinations thereof.
  • a stent 10 is illustrated, which is broadly defined to include any inter- or intraluminal device used for the release of an active ingredient, for upholding the luminal patency, and/or for the incorporation of radiopaque or radioactive materials.
  • stents include self-expandable stents, balloon-expandable stents, and stent-grafts.
  • Stent 10 can be made of a metallic material or an alloy such as, but not limited to, stainless steel (316L), "MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
  • MP35N and MP20N are trade names for alloys of cobalt, nickel, chromium and molybdenum available from standard Press Steel Co., Jenkintown, PA.
  • “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum.
  • MP20N consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
  • Stents made from bioabsorbable or biostable polymers could also be used with. the embodiments of the present invention.
  • Figures 2A-2G illustrate a method for coating stent 10 in accordance with several embodiments of the invention.
  • Figure 2A illustrates a segment of the body or substrate 12 of stent 10, wherein reference number 14 denotes the outer surface or the tissue contacting surface of stent 10. The illustrations have been simplified for ease of understanding and describing the embodiments of the present invention.
  • Figure 2B illustrates a first layer 16 formed on substrate 12.
  • First layer 16 can be of any suitable thickness.
  • the thickness of first layer 16 can be from about 0.1 micron to about 20 microns, more narrowly from about 2 microns to about 10 microns.
  • first layer 16 can have a thickness of about 3 microns.
  • First layer 16 can be made from a polymeric material. Polymers having a high coefficient of extinction, which allows the material to burn quickly and easily, can be used.
  • the coefficient of extinction k is defined by Equation 1.
  • a suitably high coefficient of extinction k can be greater than or equal to 1 x 10 4 cm "1 .
  • polymers having such a coefficient of extinction include polyimide, segmented polyurethane, and polycarbonate. Such polymers may be particularly suitable for preventing melting defects when the patterning of first layer 16 is accomplished using a laser discharge as described below.
  • First layer 16 can be deposited by any conventional method such as immersing substrate 12 in or spraying substrate 12 with a first composition containing a dissolved mixture of a first solvent with a first polymer and allowing the first solvent to evaporate from first layer 16.
  • the polymer-solvent combination should be capable of forming first layer 16 as a uniform film, rather than in a powdered form, on substrate 12.
  • First layer 16, as illustrated in Figure 2C, is patterned by removing or etching portions of first layer 16 to form vias 18 to expose surface 14 of substrate 12 not covered by first layer 16.
  • Nias 18 can be formed by, for example, exposing first layer 16 to a laser discharge such as that produced by an excimer laser.
  • the width of vias 18 is dependent on a variety of factors, such as the size of stent struts and the coating pattern that is desired.
  • vias 18 can be from about 5 microns to about 500 microns, for example about 100 microns wide.
  • Second layer 20 containing a first substance, is deposited on substrate 12 to cover the remaining portions of first layer 16 and vias 18.
  • Second layer 20 can be made of any suitable polymeric material and can be of any suitable thickness.
  • the thickness of second layer 20 can be from about 0.1 micron to about 15 microns, more narrowly from about 1 micron to about 10 microns. By way of example, second layer 20 can have a thickness of about 5 microns.
  • the polymeric material for second layer 20 should possess good adhesive qualities to surface 14 of stent 10. If a radially expandable stent 10 is used, the polymeric material should be capable of expanding with stent 10 without significant detachment or fragmenting of the material from surface 14 of stent 10.
  • the polymeric material should be a biocompatible polymer, either bio-stable or bio-absorbable in nature. One example of such a polymer is ethylene vinyl alcohol co-polymer.
  • Second layer 20 can be deposited by immersing substrate 12 in or spraying substrate 12 with a second composition containing a second solvent, a second polymer, and the first substance and allowing the second solvent to evaporate.
  • the polymer-solvent combination selected should be capable of forming second layer 20 as a uniform film, rather than in a powdered form, on substrate 12.
  • the second solvent should be capable of placing the polymer of the second layer 20 into solution but should not be capable of removing the remaining portions of first layer 16. In other words, the second solvent should not dissolve first layer 16 during the application of the second composition.
  • first layer 16 can be removed, as illustrated in Figure 2E, to pattern second layer 20.
  • the remaining portions of first layer 16 can be removed by the application of a solvent, such as the first solvent used to form first layer 16.
  • the solvent should be capable of removing or dissolving the remaining portions of first layer 16.
  • the polymeric material from which second layer 20 is made should not be capable of being dissolved during the application of the solvent. Removal of the remaining portions of first layer 16 also causes the portions of second layer 20 that are disposed over first layer 16 to be physically removed or broken-off. Portions of second layer 20 that are in contact with surface 14 remain attached to substrate 12.
  • a third layer 22, containing a second substance can ⁇ be deposited on substrate 12 to cover the patterned second layer 20 and the exposed portions of surface 14.
  • the second substance can be the same as or different than the first substance.
  • Third layer 22 can be deposited by applying a composition containing a third solvent, the second substance, and a polymeric material to stent 10.
  • the polymer-solvent combination selected should be capable of forming third layer 22 as a uniform film, rather than in a powdered form.
  • the third solvent should not remove second layer 20 or adversely affect the first substance contained in the second layer 20.
  • the profile of third layer 22 can be reduced so as to create an alternating pattern of second layer 20 and third layer 22.
  • the resulting stent 10 includes a low profile coating defined by discontinuous second layer 20 interrupted by third layer 22.
  • the discontinuous second layer 20 and third layer 22 can carry a first and a second substance, respectively, for release of the substances at different rates in situ.
  • the first and second substances can be any active ingredient capable of exerting a therapeutic or prophylactic effect in the practice of the present invention.
  • active ingredients include antiproliferative, antineoplastic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, and antioxidant substances as well as combinations thereof.
  • a suitable example of an antiproliferative substance is actinomycin D, or derivatives and analogs thereof. Synonyms of actinomycin D include dactinomycin, actinomycin IN, actinomycin I ⁇ , actinomycin X l s and actinomycin . Examples of suitable antineoplastics include paclitaxel and docetaxel.
  • antiplatelets examples include sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogs, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ilb/TLIa platelet membrane receptor antagonist, recombinant hirudin, thrombin inhibitor (available from Biogen), and 7E- 3B® (an antiplatelet drug from Centocore).
  • sodium heparin low molecular weight heparin
  • hirudin argatroban
  • argatroban forskolin
  • vapiprost vapiprost
  • prostacyclin and prostacyclin analogs dextran
  • D-phe-pro-arg-chloromethylketone synthetic antithrombin
  • dipyridamole dipyridamole
  • Suitable antimitotic agents include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin, and mitamycin.
  • suitable cytostatic or antiproliferative agents include angiopeptin (a somatostatin analog from Ibsen), angiotensin converting enzyme inhibitors such as CAPTOPRLL (available from Squibb), CE AZAPRIL (available from Hoffman -LaRoche), or LISINOPRLL (available from Merck); calcium channel blockers (such as Nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3 -fatty acid), histamine antagonist, LONASTATLN (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug from Merck), monoclonal antibodies (such as PDGF receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitor (available form Glazo), Surmin (
  • compositions to the active ingredient include alpha-interferon, genetically engineered epithelial cells, and dexamethasone. Exposure of the composition to the active ingredient is not permitted to adversely alter the active ingredient's composition or characteristic. Accordingly, the particular active ingredient is selected for compatibility with the blended polymer-solvent.
  • the dosage or concentration of the active ingredient required to produce a favorable therapeutic effect should be less than the level at which the active ingredient produces toxic effects and greater than the level at which non-therapeutic results are obtained.
  • the dosage or concentration of the active ingredient required can depend upon factors such as the particular circumstances of the patient; the nature of the trauma; the nature of the therapy desired; the time over which the ingredient administered resides at the treatment site; and if other bioactive substances are employed, the nature and type of the substance or combination of substances.
  • Therapeutic effective dosages can be determined empirically, for example by infusing vessels from suitable animal model systems and using immunohistochemical, fluorescent or electron microscopy methods to detect the agent and its effects, or by conducting suitable in vitro studies. Standard pharmacological test procedures to determine dosages are understood by one of ordinary skill in the art.
  • the first and/or second substances can be radiopaque elements or radioactive isotopes.
  • radiopaque elements include, but are not limited to, gold, tantalum, and platinum.
  • An example of a radioactive isotope is P 32 .
  • Sufficient amounts of such substances may be dispersed in the composition. By dispersed it is meant that the substances are not present in the composition as agglomerates or floes. Certain substances will disperse with ordinary mixing, such as by stirring with a stir bar, vortexing, and similar perturbation techniques.
  • the substances can be dispersed by high shear processes such as ball mill, disc mill, sand mill, attritor, rotor stator mixer, or ultrasonication — all such high shear dispersion techniques being well known to one of ordinary skill in the art.
  • Agents in the form of surfactants, emulsifiers, or stablilizers may also be added to the composition to assist in dispersion.
  • an optional primer layer 24, free from any substances, can be formed on surface 14 of substrate 12 prior to the formation of first layer 16. The presence of a substance in second layer 20 can interfere with the ability of second layer 20 to adhere effectively to surface 14 of substrate 12.
  • the primer layer 24 serves as a functionally useful intermediary layer between surface 14 of substrate 12 and the substance-containing second layer 20.
  • the primer layer 24 provides for an adhesive tie which, in effect, would also allow for the quantity of the substance in the second layer 20 to be increased without compromising the ability of second layer 20 to be effectively contained on substrate 12 during delivery and, if applicable, expansion of stent 10.
  • the deposited primer composition should be exposed to a heat treatment at a temperature range greater than about the glass transition temperature (T g ) and less than about the melting temperature (T m ) of the selected polymer.
  • T g glass transition temperature
  • T m melting temperature
  • Figures 3A-3F correspond to the above-described Figures 2B-2G, respectively, but for the initial formation of primer layer 24 directly onto surface 14 of substrate 12.
  • Figure 3 A illustrates the formation of first layer 16 on primer layer 24.
  • First layer 16 is patterned to form vias 18, as depicted in Figure 3B.
  • the underlying primer layer 24 should remain essentially undisturbed on surface 14 of substrate 12.
  • second layer 20, containing a first substance is deposited on the substrate 12 to cover the remaining portions of first layer 16 and vias 18.
  • the polymeric material selected for second layer 20 should possess good adhesive qualities to primer layer 24.
  • the remaining portions of first layer 16 are removed, as illustrated in Figure 3D, to pattern second layer 20.
  • a third layer 22, containing a second substance can be deposited on second layer 20.
  • the second substance can be the same as or different than the first substance.
  • the profile of third layer 22 can be reduced so as to create an alternating pattern of second layer 20 and third layer 22, being adhesively tied to stent 10 via primer layer 24, and containing a combination of first and second substances that are capable of being released at different rates in situ.
  • Figures 4A-4F illustrate a method of coating stent 10 in accordance with several other embodiments of the present invention.
  • Figure 4A illustrates first layer 16 formed on substrate 12.
  • First layer 16 may be made from any suitable material and can be of any suitable thickness. The thickness of first layer 16 can be from about 0.5 micron to about 10 microns, more narrowly from about 2 microns to about 8 microns. By way of example, first layer 16 can have a thickness of about 3 microns.
  • First layer 16 can be made from a polymeric material. Polymers having a high coefficient of extinction, as discussed above, are suitable.
  • First layer 16 can be deposited by any conventional method such as immersing substrate 12 in or spraying substrate 12 with a first composition containing a dissolved mixture of a first solvent with the polymer and allowing the first solvent to evaporate from first layer 16.
  • First layer 16, as illustrated in Figure 4B, is patterned by removing or etching portions of first layer 16 to form vias 18. Additionally, portions of substrate 12 underlying the removed portions of first layer 16 are removed or etched to form depots 26. Depots 26 can be formed by, for example, exposing first layer 16 and the underlying substrate 12 to a laser discharge such as that produced by an excimer laser.
  • Second layer 20 containing a first substance, is deposited on the substrate 12 to fill depots 26 and vias 18 and to cover the remaining portions of first layer 16.
  • Second layer 20 can be made of a polymeric material having good adhesive qualities to substrate 12.
  • a polymer is ethylene vinyl alcohol co-polymer.
  • first layer 16 Following the application of second layer 20, the remaining portions of first layer 16 are removed, as illustrated in Figure 4D, to pattern second layer 20.
  • the remaining portions of first layer 16 can be removed by the application of a solvent, such as the first solvent used to form first layer 16.
  • the polymeric material from which second layer 20 is made should not be capable of being removed or dissolved during the application of the solvent. Removal of the remaining portions of first layer 16 also causes the portions of second layer 20 that are disposed over first layer 16 to be physically removed or broken-off. Portions of second layer 20 that are within depots 26 remain attached to substrate 12. As illustrated in Figure 4E, the profile of second layer 20 can be reduced so as to remove the portions of second layer 20 extending above surface 14.
  • a third layer 22 containing a second substance can be deposited on substrate 12 to cover second layer 20 within depots 26 as well as surface 14.
  • the second substance can be the same as or different than the first substance.
  • Third layer 22 can be made of any suitable polymeric material and can be of any suitable thickness. The thickness of third layer 22 can be from about 0.2 microns to about 10 microns, more narrowly from about 2 microns to about 8 microns. By way of example, third layer 22 can have a thickness of about 5 microns.
  • the resulting stent 10 includes a first substance within depots 26 and a second substance in third layer 22, each of which is capable of being released at a different rate in situ.
  • Figures 5A-5H illustrate a method of coating stent 10 in accordance with other embodiments of the present invention.
  • Figure 5 A illustrates a first layer 28, containing a first substance.
  • the thickness of first layer 28 can be from about 0.2 micron to about 10 micron, more narrowly from about 2 microns to about 8 microns.
  • first layer 28 can have a thickness of about 5 microns.
  • Figure 5B illustrates a second layer 30 formed on substrate 12 to cover first layer 28.
  • the thickness of second layer 30 can be from about 1 micron to about 10 microns, more narrowly from about 2 microns to about 8 microns.
  • second layer 30 can have a thickness of about 4 microns.
  • Second layer 30 can be made from a polymeric material such as, but not limited to, polyurethanes or parylene.
  • Second layer 30, as illustrated in Figure 5C, is patterned by removing portions of second layer 30 to form vias 18, to expose portions of first layer 28 not covered by second layer 30.
  • Nias 18 can be formed by, for example, exposing second layer 30 to a laser discharge.
  • First layer 28 is patterned by removing portions of first layer 28 not covered by the remaining portions of second layer 20, as illustrated in Figure 5D.
  • First layer 28 can be patterned by exposing the uncovered portions of first layer 28 to a solvent so as to remove or dissolve the selected portions of first layer 28.
  • the remaining portions of second layer 30 can be removed, as illustrated in Figure 5E by, for example, exposing second layer 30 to a laser discharge. Alternatively, the remaining portions of second layer 30 can be removed by the application of a solvent.
  • the solvent should be capable of removing or dissolving the remaining portions of second layer 20, but should not remove the polymeric material from which first layer 28 is made or adversely affect the first substance.
  • a third layer 32 containing a second substance, is deposited on substrate 12 to cover the remaining portion of first layer 28 and vias 18.
  • Third layer 32 can be made of any suitable polymeric material and can be of any suitable thickness.
  • the solvent used to form third layer 32 should be capable of placing the polymer of the third layer 32 into solution, but should not be capable of removing the remaining portions of first layer 28. In other words, the solvent should not dissolve first layer 28 during the application of the third solution.
  • the profile of third layer 32 can optionally be reduced so as to create an alternating pattern of first layer 28 and third layer 32 having essentially the same thickness, as depicted in Figure 5G.
  • a fourth layer 34 can be deposited on the alternating pattern of first layer 28 and third layer 32, as illustrated in Figure 5H.
  • fourth layer 34 functions as a diffusion barrier for the first and second substances in first layer 28 and third layer 32, respectively.
  • Fourth layer 34 can also contain a third substance.
  • the third substance can be the same as or different than the first and second substances.
  • the resulting stent 10 includes a low profile coating having a combination of first, second and third substances that are capable of being released at different rates in situ.
  • a primer layer (not shown) can also be employed.
  • high temperature heating in a furnace may be employed to incinerate all polymers on substrate 12.
  • This polymer removal technique is particularly suitable when gold or platinum has been deposited as the first substance.
  • one or more active ingredient can be applied to a device, e.g., a stent, retained on the stent during delivery and expansion of the stent, and released at a desired control rate and for a predetermined duration of time at the site of implantation.
  • a stent having the above- described coating is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in bile ducts, esophagus, trachea/bronchi and other biological passageways.
  • a stent having the above-described coating is particularly useful for treating occluded regions of blood vessels caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, thrombosis, or restenosis.
  • Stents may be placed in a wide array of blood vessels, both arteries and veins. Representative examples of sites include the iliac, renal, and coronary arteries.
  • an angiogram is first performed to determine the appropriate positioning for stent therapy.
  • Angiography is typically accomplished by injecting a radiopaque contrast agent through a catheter inserted into an artery or vein as an x-ray is taken.
  • a guidewire is then advanced through the lesion or proposed site of treatment.
  • Over the guidewire is passed a delivery catheter which allows a stent in its collapsed configuration to be inserted into the passageway.
  • the delivery catheter is inserted either percutaneously or by surgery into the femoral artery, brachial artery, femoral vein, or brachial vein, and advanced into the appropriate blood vessel by steering the catheter through the vascular system under fluoroscopic guidance.
  • a stent having the above- described coating may then be expanded at the desired area of treatment.
  • a post insertion angiogram may also be utilized to confirm appropriate positioning.

Abstract

A coating for a stent and methods for coating a stent are provided. The coating may be used for the sustained delivery of an active ingredient or a combination of active ingredients.

Description

A COATING FOR A STENT AND A METHOD OF FORMING THE SAME
BACKGROUND OF THE INVENTION
Field of the Invention
[0001] The invention relates to implantable devices or endoluminal prostheses, such as stents. More particularly, this invention relates to a coating for a stent and methods for making the same.
Description of the Background
[0002] Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced percutaneoύsly into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially press against the atherosclerotic plaque of the lesion for remodeling of the vessel wall. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature. [0003] A problem associated with the above procedure includes formation of intimal flaps or torn arterial linings, which can collapse and occlude the conduit after the balloon is deflated. Nasospasms and recoil of the vessel wall also threaten vessel closure. Moreover, thrombosis and restenosis of the artery may develop over several months after the procedure, which may necessitate another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce the chance of the development of thrombosis and restenosis, an expandable, intraluminal prosthesis, one example of which is a stent, is implanted in the lumen to maintain the vascular patency.
[0004] Stents act as scaffoldings, functioning to physically hold open and, if desired, to expand the wall of the passageway. Typically stents are capable of being compressed, so that they can be inserted through small cavities via catheters, and then expanded to a larger diameter once they are at the desired location. Examples in the patent literature disclosing stents that have been applied in PTCA procedures include U.S. Patent No. 4,733,665 issued to Palmaz, U.S. Patent No. 4,800,882 issued to Gianturco, and U.S. Patent No. 4,886,062 issued to Wiktor. Mechanical intervention via stents has reduced the rate of restenosis as compared to balloon angioplasty. Yet, restenosis is still a significant clinical problem with rates ranging from 20-40%. When restenosis does occur in the stented segment, its treatment can be challenging, as clinical options are more limited as compared to lesions that were treated solely with a balloon. [0005] Stents are used not only for mechanical intervention but also as vehicles for providing biological therapy. Biological therapy can be achieved by medicating the stents. Medicated stents provide for the local administration of a therapeutic substance at the diseased site. In order to provide an efficacious concentration to the treated site,
systemic administration of such medication often produces adverse or even toxic side effects for the patient. Local delivery is a preferred method of treatment in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. .Local delivery thus produces fewer side effects and achieves more favorable results. This invention provides for a stent coating capable of sustained local delivery of therapeutic substances and methods of forming the coating.
SUMMARY OF THE INVENTION
[0006] A method of coating a stent is provided. The method includes forming a first layer supported by a stent substrate and patterning the first layer by removing portions of the first layer.
[0007] In some embodiments, the method additionally includes forming a primer layer on the surface of the stent substrate prior to forming the first layer.
[0008] In other embodiments, the method includes forming a second layer on the remaining portions of the first layer. The first layer may contain a first substance and the second layer may contain a second substance different than the first substance. The first and second substances may be active ingredients, radiopaque elements, or radioactive isotopes.
[0009] In other embodiments, the act of patterning the first layer includes forming a second layer on the surface of the stent prior to forming the first layer. The second layer is patterned to form vias in the second layer. Such patterning may be performed by applying a laser discharge to selected areas of the second layer. The first layer is formed on the remaining portions of the second layer and in the vias. The second layer is patterned to remove portions of the first layer disposed on the remaining portion of the second layer to pattern the first layer.
[0010] In still other embodiments, the act of patterning the first layer includes forming a second layer on the surface of the stent prior to forming the first layer and patterning the second layer to expose portions of the surface of the stent. The act of patterning the first layer also includes forming depots in the stent between the remaining portions of the second layer, wherein the first layer fills the depots, and removing the remaining portions of the second layer to remove portions of the first layer disposed on the remaining portions of the second layer, wherein the first layer remains in the depots. A third layer may be formed on the surface of the stent and over the first layer in the depots.
[0011] In still other embodiments, the act of patterning the first layer includes forming a second layer on the first layer and patterning the second layer to form vias in the second layer to expose portions of the first layer. The act of patterning the first layer also includes removing the exposed portions of the first layer, wherein portions of the first layer positioned underneath the remaining portions of the second layer remain essentially undisturbed, and removing the remaining portions of the second layer to form a patterned first layer. A third layer may be formed on the remaining portions of the first layer.
[0012] A coated stent produced in accordance with the various methods is also provided. The coated stent includes a first layer and a discontinuous second layer separated by the first layer. The first layer is a discontinuous layer separated by the second layer so as to create an alternating pattern of the first and second layers on the surface of the stent. In accordance with another embodiment, the discontinuous first and second layers can be disposed on a primer layer.
BRIEF DESCRIPTION OF THE FIGURES
[0013] Figure 1 illustrates a stent.
[0014] Figures 2A-2G illustrate a method of coating a stent in accordance with . several embodiments of the invention.
[0015] Figures 3 A-3F illustrate a method of coating a stent in accordance with several other embodiments of the invention.
[0016] Figures 4A-4F illustrate a method of coating a stent in accordance with several other embodiments of the invention. [0017] Figures 5A-5H illustrate a method of coating a stent in accordance with several other embodiments of the invention.
DETAILED DESCRIPTION
[0018] "Polymer," "poly," and "polymeric" are defined as compounds that are the product of a polymerization reaction and are inclusive of homopolymers, copolymers, terpolymers etc., including random, alternating, block, and graft variations thereof. Representative examples of polymers that can be used with the embodiments of the present invention include ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name ENAL), polyhydroxy alkanoates such as (poly(hydroxyvalerate)), (poly(hydroxybutyrate)), and (poly(hydroxybutyrate-co- valerate)); poly(L-lactic acid); polycaprolactone; poly(lactide-co-glycolide); polydioxanone; polyorthoester; polyanhydride; poly(glycolic acid); poly(D,L-lactic acid); poly(glycolic acid-co-trimethylene carbonate); polyphosphoester; polyphosphoester urethane; poly(amino acids); cyanoacrylates; poly(trimethylene carbonate); poly(iminocarbonate); cbpoly(ether-esters) (e.g. PEO/PLA); polyalkylene oxalates; polyphosphazenes and biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid; polyurethanes; silicones; polyesters; polyolefins; polyisobutylene and ethylene- alphaolefin copolymers; acrylic polymers and copolymers; vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics, such as polystyrene; polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene- methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene- vinyl acetate copolymers; polyamides, such as Nylon 66 and polycaprolactam; alkyd resins; polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins; polyurethanes; rayon; rayon-triacetate; cellulose; cellulose acetate; cellulose butyrate; cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose prbpionate; cellulose ethers; and carboxymethyl cellulose.
[0019] "Solvent" is defined as a liquid substance or composition which is compatible with the polymer and is capable of dissolving the polymer at the concentration desired in the composition. Examples of solvents include, but are not limited to, dimethylsulfoxide (DMSO), chloroform, acetone, water (buffered saline), xylene, methanol, ethanol, 1-propanol, tetrahydrofuran, 1-butanone, dimethylformamide, dimethylacetamide, cyclohexanone, ethyl acetate, methylethylketone, propylene glycol monomethylether, isopropanol, isopropanol admixed with water, N-methyl pyrrolidinone, toluene, and combinations thereof.
[0020] The Figures have not been drawn to scale, and the dimensions such as depth and thickness of the various regions and layers have been over or under emphasized for illustrative purposes. Referring to Figure 1, a stent 10 is illustrated, which is broadly defined to include any inter- or intraluminal device used for the release of an active ingredient, for upholding the luminal patency, and/or for the incorporation of radiopaque or radioactive materials. Examples of stents include self-expandable stents, balloon-expandable stents, and stent-grafts. Stent 10 can be made of a metallic material or an alloy such as, but not limited to, stainless steel (316L), "MP35N," "MP20N," ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. "MP35N" and "MP20N" are trade names for alloys of cobalt, nickel, chromium and molybdenum available from standard Press Steel Co., Jenkintown, PA. "MP35N" consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. "MP20N" consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Stents made from bioabsorbable or biostable polymers could also be used with. the embodiments of the present invention.
[0021] Figures 2A-2G illustrate a method for coating stent 10 in accordance with several embodiments of the invention. Figure 2A illustrates a segment of the body or substrate 12 of stent 10, wherein reference number 14 denotes the outer surface or the tissue contacting surface of stent 10. The illustrations have been simplified for ease of understanding and describing the embodiments of the present invention. Figure 2B illustrates a first layer 16 formed on substrate 12. First layer 16 can be of any suitable thickness. The thickness of first layer 16 can be from about 0.1 micron to about 20 microns, more narrowly from about 2 microns to about 10 microns. By way of example, first layer 16 can have a thickness of about 3 microns. First layer 16 can be made from a polymeric material. Polymers having a high coefficient of extinction, which allows the material to burn quickly and easily, can be used. The coefficient of extinction k is defined by Equation 1.
k = {Ln(I0/If) } / h (Equation 1)
Where k = coefficient of extinction (cm"1) Io = initial intensity If = final intensity h = distance at final intensity (cm)
[0022] A suitably high coefficient of extinction k can be greater than or equal to 1 x 104 cm"1. Examples of polymers having such a coefficient of extinction include polyimide, segmented polyurethane, and polycarbonate. Such polymers may be particularly suitable for preventing melting defects when the patterning of first layer 16 is accomplished using a laser discharge as described below.
[0023] First layer 16 can be deposited by any conventional method such as immersing substrate 12 in or spraying substrate 12 with a first composition containing a dissolved mixture of a first solvent with a first polymer and allowing the first solvent to evaporate from first layer 16. The polymer-solvent combination should be capable of forming first layer 16 as a uniform film, rather than in a powdered form, on substrate 12.
[0024] First layer 16, as illustrated in Figure 2C, is patterned by removing or etching portions of first layer 16 to form vias 18 to expose surface 14 of substrate 12 not covered by first layer 16. Nias 18 can be formed by, for example, exposing first layer 16 to a laser discharge such as that produced by an excimer laser. The width of vias 18 is dependent on a variety of factors, such as the size of stent struts and the coating pattern that is desired. By way of example, vias 18 can be from about 5 microns to about 500 microns, for example about 100 microns wide.
[0025] Referring to Figure 2D, a second layer 20, containing a first substance, is deposited on substrate 12 to cover the remaining portions of first layer 16 and vias 18. Second layer 20 can be made of any suitable polymeric material and can be of any suitable thickness. The thickness of second layer 20 can be from about 0.1 micron to about 15 microns, more narrowly from about 1 micron to about 10 microns. By way of example, second layer 20 can have a thickness of about 5 microns. The polymeric material for second layer 20 should possess good adhesive qualities to surface 14 of stent 10. If a radially expandable stent 10 is used, the polymeric material should be capable of expanding with stent 10 without significant detachment or fragmenting of the material from surface 14 of stent 10. The polymeric material should be a biocompatible polymer, either bio-stable or bio-absorbable in nature. One example of such a polymer is ethylene vinyl alcohol co-polymer.
[0026] Second layer 20 can be deposited by immersing substrate 12 in or spraying substrate 12 with a second composition containing a second solvent, a second polymer, and the first substance and allowing the second solvent to evaporate. The polymer-solvent combination selected should be capable of forming second layer 20 as a uniform film, rather than in a powdered form, on substrate 12. The second solvent should be capable of placing the polymer of the second layer 20 into solution but should not be capable of removing the remaining portions of first layer 16. In other words, the second solvent should not dissolve first layer 16 during the application of the second composition.
[0027] Following the application of second layer 20, the remaining portions of first layer 16 can be removed, as illustrated in Figure 2E, to pattern second layer 20. The remaining portions of first layer 16 can be removed by the application of a solvent, such as the first solvent used to form first layer 16. The solvent should be capable of removing or dissolving the remaining portions of first layer 16. The polymeric material from which second layer 20 is made should not be capable of being dissolved during the application of the solvent. Removal of the remaining portions of first layer 16 also causes the portions of second layer 20 that are disposed over first layer 16 to be physically removed or broken-off. Portions of second layer 20 that are in contact with surface 14 remain attached to substrate 12.
[0028] Referring to Figure 2F, a third layer 22, containing a second substance, can ■ be deposited on substrate 12 to cover the patterned second layer 20 and the exposed portions of surface 14. The second substance can be the same as or different than the first substance. Third layer 22 can be deposited by applying a composition containing a third solvent, the second substance, and a polymeric material to stent 10. The polymer-solvent combination selected should be capable of forming third layer 22 as a uniform film, rather than in a powdered form. The third solvent should not remove second layer 20 or adversely affect the first substance contained in the second layer 20. As an optional step, as illustrated in Figure 2G, the profile of third layer 22 can be reduced so as to create an alternating pattern of second layer 20 and third layer 22. The resulting stent 10 includes a low profile coating defined by discontinuous second layer 20 interrupted by third layer 22. The discontinuous second layer 20 and third layer 22 can carry a first and a second substance, respectively, for release of the substances at different rates in situ.
[0029] The first and second substances can be any active ingredient capable of exerting a therapeutic or prophylactic effect in the practice of the present invention. Examples of such active ingredients include antiproliferative, antineoplastic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, and antioxidant substances as well as combinations thereof.
[0030] A suitable example of an antiproliferative substance is actinomycin D, or derivatives and analogs thereof. Synonyms of actinomycin D include dactinomycin, actinomycin IN, actinomycin Iχ, actinomycin Xl s and actinomycin . Examples of suitable antineoplastics include paclitaxel and docetaxel. Examples of suitable antiplatelets, anticoagulants, antifibrins, and antithrombins include sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogs, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ilb/TLIa platelet membrane receptor antagonist, recombinant hirudin, thrombin inhibitor (available from Biogen), and 7E- 3B® (an antiplatelet drug from Centocore). Examples of suitable antimitotic agents include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin, and mitamycin. Examples of suitable cytostatic or antiproliferative agents include angiopeptin (a somatostatin analog from Ibsen), angiotensin converting enzyme inhibitors such as CAPTOPRLL (available from Squibb), CE AZAPRIL (available from Hoffman -LaRoche), or LISINOPRLL (available from Merck); calcium channel blockers (such as Nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3 -fatty acid), histamine antagonist, LONASTATLN (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug from Merck), monoclonal antibodies (such as PDGF receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitor (available form Glazo), Surmin (a PDGF antagonist), serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, and dexamethasone. Exposure of the composition to the active ingredient is not permitted to adversely alter the active ingredient's composition or characteristic. Accordingly, the particular active ingredient is selected for compatibility with the blended polymer-solvent.
[0031] The dosage or concentration of the active ingredient required to produce a favorable therapeutic effect should be less than the level at which the active ingredient produces toxic effects and greater than the level at which non-therapeutic results are obtained. The dosage or concentration of the active ingredient required can depend upon factors such as the particular circumstances of the patient; the nature of the trauma; the nature of the therapy desired; the time over which the ingredient administered resides at the treatment site; and if other bioactive substances are employed, the nature and type of the substance or combination of substances. Therapeutic effective dosages can be determined empirically, for example by infusing vessels from suitable animal model systems and using immunohistochemical, fluorescent or electron microscopy methods to detect the agent and its effects, or by conducting suitable in vitro studies. Standard pharmacological test procedures to determine dosages are understood by one of ordinary skill in the art. r
[0032] In accordance with another embodiment, the first and/or second substances can be radiopaque elements or radioactive isotopes. Examples of radiopaque elements include, but are not limited to, gold, tantalum, and platinum. An example of a radioactive isotope is P32. Sufficient amounts of such substances may be dispersed in the composition. By dispersed it is meant that the substances are not present in the composition as agglomerates or floes. Certain substances will disperse with ordinary mixing, such as by stirring with a stir bar, vortexing, and similar perturbation techniques. Otherwise, the substances can be dispersed by high shear processes such as ball mill, disc mill, sand mill, attritor, rotor stator mixer, or ultrasonication — all such high shear dispersion techniques being well known to one of ordinary skill in the art. Agents in the form of surfactants, emulsifiers, or stablilizers may also be added to the composition to assist in dispersion. [0033] Referring to Figures 3A-3F, an optional primer layer 24, free from any substances, can be formed on surface 14 of substrate 12 prior to the formation of first layer 16. The presence of a substance in second layer 20 can interfere with the ability of second layer 20 to adhere effectively to surface 14 of substrate 12. High drug loadings of 10-40% by weight in the matrix may significantly hinder the retention of second layer 20 on surface 14 of substrate 12. The primer layer 24 serves as a functionally useful intermediary layer between surface 14 of substrate 12 and the substance-containing second layer 20. The primer layer 24 provides for an adhesive tie which, in effect, would also allow for the quantity of the substance in the second layer 20 to be increased without compromising the ability of second layer 20 to be effectively contained on substrate 12 during delivery and, if applicable, expansion of stent 10.
[0034] With the use of thermoplastic polymers such as, but not limited to, ethylene vinyl alcohol copolymer, polycaprolactone, poly(lactide-co-glycolide), and poly(hydroxybutyrate), the deposited primer composition should be exposed to a heat treatment at a temperature range greater than about the glass transition temperature (Tg) and less than about the melting temperature (Tm) of the selected polymer. Unexpected results have been discovered with treatment of the composition under this temperature range, specifically strong adhesion or bonding of the coating to the metallic surface of a stent 10. The prosthesis should be exposed to the heat treatment for any suitable duration of time that will allow for the formation of primer layer 24 on surface 14 of substrate 12 and for the evaporation of the solvent employed.
[0035] Figures 3A-3F correspond to the above-described Figures 2B-2G, respectively, but for the initial formation of primer layer 24 directly onto surface 14 of substrate 12. Briefly, Figure 3 A illustrates the formation of first layer 16 on primer layer 24. First layer 16 is patterned to form vias 18, as depicted in Figure 3B. The underlying primer layer 24 should remain essentially undisturbed on surface 14 of substrate 12. In Figure 3C, second layer 20, containing a first substance, is deposited on the substrate 12 to cover the remaining portions of first layer 16 and vias 18. The polymeric material selected for second layer 20 should possess good adhesive qualities to primer layer 24. Following the application of second layer 20, the remaining portions of first layer 16 are removed, as illustrated in Figure 3D, to pattern second layer 20. Referring to Figure 3E, a third layer 22, containing a second substance, can be deposited on second layer 20. The second substance can be the same as or different than the first substance. As an optional step, as illustrated in Figure 3F, the profile of third layer 22 can be reduced so as to create an alternating pattern of second layer 20 and third layer 22, being adhesively tied to stent 10 via primer layer 24, and containing a combination of first and second substances that are capable of being released at different rates in situ.
[0036] Figures 4A-4F illustrate a method of coating stent 10 in accordance with several other embodiments of the present invention. Figure 4A illustrates first layer 16 formed on substrate 12. First layer 16 may be made from any suitable material and can be of any suitable thickness. The thickness of first layer 16 can be from about 0.5 micron to about 10 microns, more narrowly from about 2 microns to about 8 microns. By way of example, first layer 16 can have a thickness of about 3 microns. First layer 16 can be made from a polymeric material. Polymers having a high coefficient of extinction, as discussed above, are suitable. First layer 16 can be deposited by any conventional method such as immersing substrate 12 in or spraying substrate 12 with a first composition containing a dissolved mixture of a first solvent with the polymer and allowing the first solvent to evaporate from first layer 16.
[0037] First layer 16, as illustrated in Figure 4B, is patterned by removing or etching portions of first layer 16 to form vias 18. Additionally, portions of substrate 12 underlying the removed portions of first layer 16 are removed or etched to form depots 26. Depots 26 can be formed by, for example, exposing first layer 16 and the underlying substrate 12 to a laser discharge such as that produced by an excimer laser.
[0038] Referring to Figure 4C, a second layer 20, containing a first substance, is deposited on the substrate 12 to fill depots 26 and vias 18 and to cover the remaining portions of first layer 16. Second layer 20 can be made of a polymeric material having good adhesive qualities to substrate 12. One example of such a polymer is ethylene vinyl alcohol co-polymer.
[0039] Following the application of second layer 20, the remaining portions of first layer 16 are removed, as illustrated in Figure 4D, to pattern second layer 20. The remaining portions of first layer 16 can be removed by the application of a solvent, such as the first solvent used to form first layer 16. The polymeric material from which second layer 20 is made should not be capable of being removed or dissolved during the application of the solvent. Removal of the remaining portions of first layer 16 also causes the portions of second layer 20 that are disposed over first layer 16 to be physically removed or broken-off. Portions of second layer 20 that are within depots 26 remain attached to substrate 12. As illustrated in Figure 4E, the profile of second layer 20 can be reduced so as to remove the portions of second layer 20 extending above surface 14.
[0040] Referring to Figure 4F, in accordance with another embodiment, a third layer 22 containing a second substance, can be deposited on substrate 12 to cover second layer 20 within depots 26 as well as surface 14. The second substance can be the same as or different than the first substance. Third layer 22 can be made of any suitable polymeric material and can be of any suitable thickness. The thickness of third layer 22 can be from about 0.2 microns to about 10 microns, more narrowly from about 2 microns to about 8 microns. By way of example, third layer 22 can have a thickness of about 5 microns. The resulting stent 10 includes a first substance within depots 26 and a second substance in third layer 22, each of which is capable of being released at a different rate in situ.
[0041] Figures 5A-5H illustrate a method of coating stent 10 in accordance with other embodiments of the present invention. Figure 5 A illustrates a first layer 28, containing a first substance. The thickness of first layer 28 can be from about 0.2 micron to about 10 micron, more narrowly from about 2 microns to about 8 microns. By way of example, first layer 28 can have a thickness of about 5 microns. Figure 5B illustrates a second layer 30 formed on substrate 12 to cover first layer 28. The thickness of second layer 30 can be from about 1 micron to about 10 microns, more narrowly from about 2 microns to about 8 microns. By way of example, second layer 30 can have a thickness of about 4 microns. Second layer 30 can be made from a polymeric material such as, but not limited to, polyurethanes or parylene.
[0042] Second layer 30, as illustrated in Figure 5C, is patterned by removing portions of second layer 30 to form vias 18, to expose portions of first layer 28 not covered by second layer 30. Nias 18 can be formed by, for example, exposing second layer 30 to a laser discharge. First layer 28 is patterned by removing portions of first layer 28 not covered by the remaining portions of second layer 20, as illustrated in Figure 5D. First layer 28 can be patterned by exposing the uncovered portions of first layer 28 to a solvent so as to remove or dissolve the selected portions of first layer 28.
[0043] The remaining portions of second layer 30 can be removed, as illustrated in Figure 5E by, for example, exposing second layer 30 to a laser discharge. Alternatively, the remaining portions of second layer 30 can be removed by the application of a solvent. The solvent should be capable of removing or dissolving the remaining portions of second layer 20, but should not remove the polymeric material from which first layer 28 is made or adversely affect the first substance. [0044] Referring to Figure 5F, a third layer 32, containing a second substance, is deposited on substrate 12 to cover the remaining portion of first layer 28 and vias 18. Third layer 32 can be made of any suitable polymeric material and can be of any suitable thickness. The solvent used to form third layer 32 should be capable of placing the polymer of the third layer 32 into solution, but should not be capable of removing the remaining portions of first layer 28. In other words, the solvent should not dissolve first layer 28 during the application of the third solution.
[0045] Following the application of third layer 32, the profile of third layer 32 can optionally be reduced so as to create an alternating pattern of first layer 28 and third layer 32 having essentially the same thickness, as depicted in Figure 5G. As another optional step, a fourth layer 34 can be deposited on the alternating pattern of first layer 28 and third layer 32, as illustrated in Figure 5H. In some embodiments, fourth layer 34 functions as a diffusion barrier for the first and second substances in first layer 28 and third layer 32, respectively. Fourth layer 34 can also contain a third substance. The third substance can be the same as or different than the first and second substances. The resulting stent 10 includes a low profile coating having a combination of first, second and third substances that are capable of being released at different rates in situ. In yet another embodiment, a primer layer (not shown) can also be employed.
[0046] In the above-described embodiments, high temperature heating in a furnace (e.g., 700 - 800 °C) may be employed to incinerate all polymers on substrate 12. This polymer removal technique is particularly suitable when gold or platinum has been deposited as the first substance.
[0047] In accordance with the above-described methods, one or more active ingredient can be applied to a device, e.g., a stent, retained on the stent during delivery and expansion of the stent, and released at a desired control rate and for a predetermined duration of time at the site of implantation. A stent having the above- described coating is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in bile ducts, esophagus, trachea/bronchi and other biological passageways. A stent having the above-described coating is particularly useful for treating occluded regions of blood vessels caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, thrombosis, or restenosis. Stents may be placed in a wide array of blood vessels, both arteries and veins. Representative examples of sites include the iliac, renal, and coronary arteries.
[0048] Briefly, an angiogram is first performed to determine the appropriate positioning for stent therapy. Angiography is typically accomplished by injecting a radiopaque contrast agent through a catheter inserted into an artery or vein as an x-ray is taken. A guidewire is then advanced through the lesion or proposed site of treatment. Over the guidewire is passed a delivery catheter which allows a stent in its collapsed configuration to be inserted into the passageway. The delivery catheter is inserted either percutaneously or by surgery into the femoral artery, brachial artery, femoral vein, or brachial vein, and advanced into the appropriate blood vessel by steering the catheter through the vascular system under fluoroscopic guidance. A stent having the above- described coating may then be expanded at the desired area of treatment. A post insertion angiogram may also be utilized to confirm appropriate positioning.
[0049] While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

Claims

CLAIMSWhat is claimed is:
1. A method of coating a stent, comprising:
(a) forming a first layer supported by a stent substrate; and
(b) patterning said first layer by removing portions of said first layer.
2. A coated stent produced in accordance with the method of Claim 1.
3. The method of Claim 1, wherein said patteming comprises:
(a) forming a second layer on the surface of said stent prior to forming said first layer;
(b) patterning said second layer to form vias in said second layer, wherein said first layer is formed on the remaining portions of said second layer and in said vias; and
(c) patterning said second layer to remove portions of said the first layer disposed on the remaining portion of said second layer to pattern said first layer.
4. The method of Claim 1, additionally comprising forming a primer layer on the surface of said stent substrate prior to forming said first layer, wherein said patterning comprises:
(a) forming a second layer on said primer layer prior to forming said first layer;
(b) patterning said second layer to form vias in said second layer, wherein said primer layer remains essentially undisturbed on the surface of said stent substrate, and wherein said first layer is formed on the remaining portions of said second layer and in said vias on said primer layer; and
(c) removing the remaining portions of said second layer to remove portions of said first layer disposed on the remaining portions of said second layer to pattern said first layer.
5. The method of Claim 1, additionally comprising forming a second layer on the remaining portions of said first layer.
6. The method of Claim 5, wherein said first layer contains a first substance and said second layer contains a second substance different than said first substance.
7. The method of Claim 6, wherein said first or second substances are selected from a group of therapeutic agents, radiopaque elements and radioactive isotopes.
8. The method of Claim 1, wherein said patterning comprises:
(a) forming a second layer on the surface of said stent prior to forming said first layer;
(b) patterning said second layer to expose portions of the surface of said stent;
(c) forming depots in said stent between the remaining portions of said second layer, wherein said first layer fills said depots; and
(d) removing the remaining portions of said second layer to remove portions of said first layer disposed on the remaining portions of said second layer, wherein said first layer remains in said depots.
9. The method of Claim 8, additionally comprising reducing the profile of said first layer such that said first layer does not protrude out from said depots.
10. The method of Claim 8, additionally comprising forming a third layer over said first layer and on the surface of said stent.
11. The method of Claim 10, wherein said first layer contains a first substance and said third layer contains a second substance different from said first substance.
12. The method of Claim 1, wherein said patterning comprises:
(a) forming a second layer on said first layer;
(b) patterning said second layer to form vias in said second layer to expose portions of said first layer;
(c) removing the exposed portions of said first layer, wherein portions of said first layer positioned underneath the remaining portions of said second layer remain essentially undisturbed; and
(d) removing the remaining portions of said second layer to form a patterned first layer.
13. The method of Claim 12, additionally comprising forming a third layer on the remaining portions of said first layer.
14. The method of Claim 13, additionally comprising reducing the profile of said third layer so as to create an alternating pattern of said first layer and said third layer.
15. The method of Claim 13, wherein said first layer contains a first substance and said third layer contains a second substance different from said first substance.
16. The method of Claim 12, wherein the coating comprises a discontinuous first layer interrupted by a second layer.
17. . A coating for a stent comprising: a first layer; and a discontinuous second layer separated by said first layer.
18. The coating of Claim 17, wherein said first layer is a discontinuous layer separated by said second layer so as to create an alternating pattern of said first layer and said second layer disposed on the surface of the stent.
19. The coating of Claim 17, additionally comprising: a primer layer disposed on the surface of the stent, wherein said first layer is a discontinuous layer separated by said second layer so as to create an alternating pattern of said first layer and said second layer disposed on said primer layer.
20. The coating of Claim 17, wherein said first layer contains a first substance and said second layer contains a second substance, and wherein the release rate of said first substance is different than the release rate of said second substance.
21. The coating of Claim 17, wherein said first substance is different than said second substance.
22. The coating of Claim 17, wherein the stent is a radially expandable stent.
PCT/US2002/011755 2001-04-24 2002-04-12 A coating for a stent and a method of forming the same WO2002085424A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/841,798 US6712845B2 (en) 2001-04-24 2001-04-24 Coating for a stent and a method of forming the same
US09/841,798 2001-04-24

Publications (1)

Publication Number Publication Date
WO2002085424A1 true WO2002085424A1 (en) 2002-10-31

Family

ID=25285712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/011755 WO2002085424A1 (en) 2001-04-24 2002-04-12 A coating for a stent and a method of forming the same

Country Status (2)

Country Link
US (3) US6712845B2 (en)
WO (1) WO2002085424A1 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005021622A1 (en) * 2005-05-05 2006-11-16 Hemoteq Gmbh A method for coating the net or mesh fabric of surgically used blood vessel stents has a first thin coating applied to the web material and a second thicker coating applied to the webs and gaps
DE102005032604A1 (en) * 2005-07-13 2007-01-18 Gfe Medizintechnik Gmbh Absorbable, insertable into the body medical element, in particular resorbable implant
DE102006007231A1 (en) * 2006-02-15 2007-08-30 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Method of wrapping a stent
DE102006038236A1 (en) * 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Biodegradable stent with an active coating
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface

Families Citing this family (283)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7179289B2 (en) 1998-03-30 2007-02-20 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20030130657A1 (en) * 1999-08-05 2003-07-10 Tom Curtis P. Devices for applying energy to tissue
US20030070676A1 (en) * 1999-08-05 2003-04-17 Cooper Joel D. Conduits having distal cage structure for maintaining collateral channels in tissue and related methods
JP2003506132A (en) * 1999-08-05 2003-02-18 ブロンカス テクノロジーズ， インコーポレイテッド Methods and devices for creating collateral channels in the lung
US20040073155A1 (en) * 2000-01-14 2004-04-15 Broncus Technologies, Inc. Methods and devices for maintaining patency of surgically created channels in tissue
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US7682647B2 (en) 1999-09-03 2010-03-23 Advanced Cardiovascular Systems, Inc. Thermal treatment of a drug eluting implantable medical device
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20050238686A1 (en) * 1999-12-23 2005-10-27 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US7682648B1 (en) 2000-05-31 2010-03-23 Advanced Cardiovascular Systems, Inc. Methods for forming polymeric coatings on stents
US6953560B1 (en) 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
ATE300255T1 (en) * 2000-10-16 2005-08-15 Conor Medsystems Inc EXPANDABLE MEDICAL DEVICE FOR DELIVERING A MEDICINE
US7807210B1 (en) 2000-10-31 2010-10-05 Advanced Cardiovascular Systems, Inc. Hemocompatible polymers on hydrophobic porous polymers
US6824559B2 (en) 2000-12-22 2004-11-30 Advanced Cardiovascular Systems, Inc. Ethylene-carboxyl copolymers as drug delivery matrices
US20040204756A1 (en) * 2004-02-11 2004-10-14 Diaz Stephen Hunter Absorbent article with improved liquid acquisition capacity
US20040220660A1 (en) * 2001-02-05 2004-11-04 Shanley John F. Bioresorbable stent with beneficial agent reservoirs
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
EP1258230A3 (en) 2001-03-29 2003-12-10 CardioSafe Ltd Balloon catheter device
US6780424B2 (en) * 2001-03-30 2004-08-24 Charles David Claude Controlled morphologies in polymer drug for release of drugs from polymer films
US7056967B2 (en) * 2001-04-10 2006-06-06 Ciba Specialty Chemicals Corporation Stabilized medium and high voltage cable insulation composition
US6656506B1 (en) 2001-05-09 2003-12-02 Advanced Cardiovascular Systems, Inc. Microparticle coated medical device
US6743462B1 (en) * 2001-05-31 2004-06-01 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating implantable devices
US6695920B1 (en) 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
WO2003002243A2 (en) 2001-06-27 2003-01-09 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US7682669B1 (en) 2001-07-30 2010-03-23 Advanced Cardiovascular Systems, Inc. Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US20040249443A1 (en) * 2001-08-20 2004-12-09 Shanley John F. Expandable medical device for treating cardiac arrhythmias
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7708712B2 (en) 2001-09-04 2010-05-04 Broncus Technologies, Inc. Methods and devices for maintaining patency of surgically created channels in a body organ
US20050060042A1 (en) * 2001-09-04 2005-03-17 Broncus Technologies, Inc. Methods and devices for maintaining surgically created channels in a body organ
US8303651B1 (en) 2001-09-07 2012-11-06 Advanced Cardiovascular Systems, Inc. Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
GB0121980D0 (en) 2001-09-11 2001-10-31 Cathnet Science Holding As Expandable stent
US7285304B1 (en) 2003-06-25 2007-10-23 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US7989018B2 (en) 2001-09-17 2011-08-02 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US6764709B2 (en) * 2001-11-08 2004-07-20 Scimed Life Systems, Inc. Method for making and measuring a coating on the surface of a medical device using an ultraviolet laser
US7137993B2 (en) 2001-12-03 2006-11-21 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US7294146B2 (en) 2001-12-03 2007-11-13 Xtent, Inc. Apparatus and methods for delivery of variable length stents
US20030135266A1 (en) * 2001-12-03 2003-07-17 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US7892273B2 (en) 2001-12-03 2011-02-22 Xtent, Inc. Custom length stent apparatus
US7147656B2 (en) * 2001-12-03 2006-12-12 Xtent, Inc. Apparatus and methods for delivery of braided prostheses
US7270668B2 (en) * 2001-12-03 2007-09-18 Xtent, Inc. Apparatus and methods for delivering coiled prostheses
US7309350B2 (en) * 2001-12-03 2007-12-18 Xtent, Inc. Apparatus and methods for deployment of vascular prostheses
US7351255B2 (en) * 2001-12-03 2008-04-01 Xtent, Inc. Stent delivery apparatus and method
US20040186551A1 (en) * 2003-01-17 2004-09-23 Xtent, Inc. Multiple independent nested stent structures and methods for their preparation and deployment
US7182779B2 (en) * 2001-12-03 2007-02-27 Xtent, Inc. Apparatus and methods for positioning prostheses for deployment from a catheter
US8080048B2 (en) 2001-12-03 2011-12-20 Xtent, Inc. Stent delivery for bifurcated vessels
US20110306997A9 (en) * 2002-02-21 2011-12-15 Roschak Edmund J Devices for creating passages and sensing for blood vessels
US7919075B1 (en) 2002-03-20 2011-04-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
EP1509168A4 (en) * 2002-04-19 2009-07-22 Broncus Tech Inc Devices for maintaining surgically created openings
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US7758636B2 (en) 2002-09-20 2010-07-20 Innovational Holdings Llc Expandable medical device with openings for delivery of multiple beneficial agents
US7125577B2 (en) * 2002-09-27 2006-10-24 Surmodics, Inc Method and apparatus for coating of substrates
USRE40722E1 (en) 2002-09-27 2009-06-09 Surmodics, Inc. Method and apparatus for coating of substrates
US7192484B2 (en) 2002-09-27 2007-03-20 Surmodics, Inc. Advanced coating apparatus and method
US20040142014A1 (en) * 2002-11-08 2004-07-22 Conor Medsystems, Inc. Method and apparatus for reducing tissue damage after ischemic injury
AU2003285195A1 (en) * 2002-11-08 2004-06-03 Innovational Holdings, Llc Method and apparatus for treating vulnerable artherosclerotic plaque
JP2006505364A (en) * 2002-11-08 2006-02-16 コナー　メドシステムズ，　インコーポレイテッド Expandable medical device and method for treating chronic total infarction using a local supply of angiogenic factors
US7169178B1 (en) * 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US6896965B1 (en) * 2002-11-12 2005-05-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices
US20050070989A1 (en) * 2002-11-13 2005-03-31 Whye-Kei Lye Medical devices having porous layers and methods for making the same
US20060121080A1 (en) * 2002-11-13 2006-06-08 Lye Whye K Medical devices having nanoporous layers and methods for making the same
US9770349B2 (en) * 2002-11-13 2017-09-26 University Of Virginia Patent Foundation Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation
CN1725988A (en) * 2002-11-13 2006-01-25 斯特根有限公司 Medical apparatus and manufacture method thereof with porous layer
US7776926B1 (en) 2002-12-11 2010-08-17 Advanced Cardiovascular Systems, Inc. Biocompatible coating for implantable medical devices
US7758880B2 (en) 2002-12-11 2010-07-20 Advanced Cardiovascular Systems, Inc. Biocompatible polyacrylate compositions for medical applications
US7074276B1 (en) 2002-12-12 2006-07-11 Advanced Cardiovascular Systems, Inc. Clamp mandrel fixture and a method of using the same to minimize coating defects
US7758881B2 (en) 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US20060002968A1 (en) 2004-06-30 2006-01-05 Gordon Stewart Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US8435550B2 (en) 2002-12-16 2013-05-07 Abbot Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7063884B2 (en) * 2003-02-26 2006-06-20 Advanced Cardiovascular Systems, Inc. Stent coating
US20040202692A1 (en) * 2003-03-28 2004-10-14 Conor Medsystems, Inc. Implantable medical device and method for in situ selective modulation of agent delivery
US20050010170A1 (en) * 2004-02-11 2005-01-13 Shanley John F Implantable medical device with beneficial agent concentration gradient
CA2519711C (en) 2003-03-28 2012-01-17 Conor Medsystems, Inc. Implantable medical device with beneficial agent concentration gradient
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US7241308B2 (en) * 2003-06-09 2007-07-10 Xtent, Inc. Stent deployment systems and methods
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US8308682B2 (en) 2003-07-18 2012-11-13 Broncus Medical Inc. Devices for maintaining patency of surgically created channels in tissue
US20050021127A1 (en) * 2003-07-21 2005-01-27 Kawula Paul John Porous glass fused onto stent for drug retention
US6840569B1 (en) * 2003-07-22 2005-01-11 Arthur Donald Leigh Caravan
US7431959B1 (en) 2003-07-31 2008-10-07 Advanced Cardiovascular Systems Inc. Method and system for irradiation of a drug eluting implantable medical device
US7645474B1 (en) 2003-07-31 2010-01-12 Advanced Cardiovascular Systems, Inc. Method and system of purifying polymers for use with implantable medical devices
US7785512B1 (en) 2003-07-31 2010-08-31 Advanced Cardiovascular Systems, Inc. Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US7704544B2 (en) 2003-10-07 2010-04-27 Advanced Cardiovascular Systems, Inc. System and method for coating a tubular implantable medical device
US7553324B2 (en) * 2003-10-14 2009-06-30 Xtent, Inc. Fixed stent delivery devices and methods
US20050080475A1 (en) * 2003-10-14 2005-04-14 Xtent, Inc. A Delaware Corporation Stent delivery devices and methods
US7192440B2 (en) * 2003-10-15 2007-03-20 Xtent, Inc. Implantable stent delivery devices and methods
US7329413B1 (en) 2003-11-06 2008-02-12 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices having gradient of hydration and methods for fabricating thereof
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US8192752B2 (en) 2003-11-21 2012-06-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same
US7560492B1 (en) 2003-11-25 2009-07-14 Advanced Cardiovascular Systems, Inc. Polysulfone block copolymers as drug-eluting coating material
US7807722B2 (en) 2003-11-26 2010-10-05 Advanced Cardiovascular Systems, Inc. Biobeneficial coating compositions and methods of making and using thereof
US7403966B2 (en) * 2003-12-08 2008-07-22 Freescale Semiconductor, Inc. Hardware for performing an arithmetic function
US7220816B2 (en) * 2003-12-16 2007-05-22 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
US7435788B2 (en) * 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US7326236B2 (en) * 2003-12-23 2008-02-05 Xtent, Inc. Devices and methods for controlling and indicating the length of an interventional element
US8309112B2 (en) 2003-12-24 2012-11-13 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same
GB0402736D0 (en) * 2004-02-06 2004-03-10 Tayside Flow Technologies Ltd A drug delivery device
EP1713453B1 (en) * 2004-02-13 2008-11-19 Conor Medsystems, Inc. Implantable drug delivery device including wire filaments
EP1744707A4 (en) * 2004-03-04 2008-09-03 Biolok Int Inc Surgical stent having micro-geometric patterned surface
US8685431B2 (en) 2004-03-16 2014-04-01 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US7744644B2 (en) * 2004-03-19 2010-06-29 Boston Scientific Scimed, Inc. Medical articles having regions with polyelectrolyte multilayer coatings for regulating drug release
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US20050208093A1 (en) 2004-03-22 2005-09-22 Thierry Glauser Phosphoryl choline coating compositions
WO2005089827A1 (en) * 2004-03-22 2005-09-29 Agency For Science, Technology And Research Method for obtaining graded pore structure in scaffolds for tissues and bone, and scaffolds with graded pore structure for tissue and bone
US7323006B2 (en) 2004-03-30 2008-01-29 Xtent, Inc. Rapid exchange interventional devices and methods
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US20050228473A1 (en) * 2004-04-05 2005-10-13 David Brown Device and method for delivering a treatment to an artery
US20050228477A1 (en) * 2004-04-09 2005-10-13 Xtent, Inc. Topographic coatings and coating methods for medical devices
US20050265960A1 (en) * 2004-05-26 2005-12-01 Pacetti Stephen D Polymers containing poly(ester amides) and agents for use with medical articles and methods of fabricating the same
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
US7820732B2 (en) 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
US9561309B2 (en) 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US20050266039A1 (en) * 2004-05-27 2005-12-01 Jan Weber Coated medical device and method for making the same
US20050271700A1 (en) * 2004-06-03 2005-12-08 Desnoyer Jessica R Poly(ester amide) coating composition for implantable devices
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
WO2006002399A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable implantable medical devices, methods and systems
US20050287287A1 (en) * 2004-06-24 2005-12-29 Parker Theodore L Methods and systems for loading an implantable medical device with beneficial agent
US8317859B2 (en) 2004-06-28 2012-11-27 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US20050288766A1 (en) 2004-06-28 2005-12-29 Xtent, Inc. Devices and methods for controlling expandable prostheses during deployment
US20050287184A1 (en) 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
US8696564B2 (en) * 2004-07-09 2014-04-15 Cardiac Pacemakers, Inc. Implantable sensor with biocompatible coating for controlling or inhibiting tissue growth
CA2591543A1 (en) * 2004-07-19 2006-02-09 Broncus Technologies, Inc. Methods and devices for maintaining patency of surgically created channels in a body organ
US8409167B2 (en) 2004-07-19 2013-04-02 Broncus Medical Inc Devices for delivering substances through an extra-anatomic opening created in an airway
US8357391B2 (en) 2004-07-30 2013-01-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages
US7494665B1 (en) 2004-07-30 2009-02-24 Advanced Cardiovascular Systems, Inc. Polymers containing siloxane monomers
US7648727B2 (en) 2004-08-26 2010-01-19 Advanced Cardiovascular Systems, Inc. Methods for manufacturing a coated stent-balloon assembly
US7244443B2 (en) 2004-08-31 2007-07-17 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrophilic monomers
EP2169090B3 (en) 2008-09-30 2014-06-25 Biotronik VI Patent AG Implant made of a biodegradable magnesium alloy
US9468704B2 (en) 2004-09-07 2016-10-18 Biotronik Vi Patent Ag Implant made of a biodegradable magnesium alloy
US7063720B2 (en) * 2004-09-14 2006-06-20 The Wallace Enterprises, Inc. Covered stent with controlled therapeutic agent diffusion
US8110211B2 (en) 2004-09-22 2012-02-07 Advanced Cardiovascular Systems, Inc. Medicated coatings for implantable medical devices including polyacrylates
US20060069424A1 (en) * 2004-09-27 2006-03-30 Xtent, Inc. Self-constrained segmented stents and methods for their deployment
US7166680B2 (en) * 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers
US8603634B2 (en) 2004-10-27 2013-12-10 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US20060089485A1 (en) * 2004-10-27 2006-04-27 Desnoyer Jessica R End-capped poly(ester amide) copolymers
US7958840B2 (en) * 2004-10-27 2011-06-14 Surmodics, Inc. Method and apparatus for coating of substrates
US7147659B2 (en) * 2004-10-28 2006-12-12 Cordis Neurovascular, Inc. Expandable stent having a dissolvable portion
US20060095122A1 (en) * 2004-10-29 2006-05-04 Advanced Cardiovascular Systems, Inc. Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same
US7390497B2 (en) 2004-10-29 2008-06-24 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
US7214759B2 (en) * 2004-11-24 2007-05-08 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
US8609123B2 (en) 2004-11-29 2013-12-17 Advanced Cardiovascular Systems, Inc. Derivatized poly(ester amide) as a biobeneficial coating
US20060115449A1 (en) * 2004-11-30 2006-06-01 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings
US7892592B1 (en) 2004-11-30 2011-02-22 Advanced Cardiovascular Systems, Inc. Coating abluminal surfaces of stents and other implantable medical devices
US7604818B2 (en) * 2004-12-22 2009-10-20 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrocarbon monomers
US7419504B2 (en) 2004-12-27 2008-09-02 Advanced Cardiovascular Systems, Inc. Poly(ester amide) block copolymers
US8007775B2 (en) 2004-12-30 2011-08-30 Advanced Cardiovascular Systems, Inc. Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US7202325B2 (en) * 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
US7402168B2 (en) * 2005-04-11 2008-07-22 Xtent, Inc. Custom-length stent delivery system with independently operable expansion elements
US7795467B1 (en) 2005-04-26 2010-09-14 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial polyurethanes for use in medical devices
US8778375B2 (en) 2005-04-29 2014-07-15 Advanced Cardiovascular Systems, Inc. Amorphous poly(D,L-lactide) coating
US7320702B2 (en) * 2005-06-08 2008-01-22 Xtent, Inc. Apparatus and methods for deployment of multiple custom-length prostheses (III)
US7938851B2 (en) * 2005-06-08 2011-05-10 Xtent, Inc. Devices and methods for operating and controlling interventional apparatus
US7622070B2 (en) 2005-06-20 2009-11-24 Advanced Cardiovascular Systems, Inc. Method of manufacturing an implantable polymeric medical device
US7823533B2 (en) 2005-06-30 2010-11-02 Advanced Cardiovascular Systems, Inc. Stent fixture and method for reducing coating defects
US8021676B2 (en) 2005-07-08 2011-09-20 Advanced Cardiovascular Systems, Inc. Functionalized chemically inert polymers for coatings
US7785647B2 (en) 2005-07-25 2010-08-31 Advanced Cardiovascular Systems, Inc. Methods of providing antioxidants to a drug containing product
US7735449B1 (en) 2005-07-28 2010-06-15 Advanced Cardiovascular Systems, Inc. Stent fixture having rounded support structures and method for use thereof
US20070128246A1 (en) * 2005-12-06 2007-06-07 Hossainy Syed F A Solventless method for forming a coating
US20070135909A1 (en) * 2005-12-08 2007-06-14 Desnoyer Jessica R Adhesion polymers to improve stent retention
US7976891B1 (en) 2005-12-16 2011-07-12 Advanced Cardiovascular Systems, Inc. Abluminal stent coating apparatus and method of using focused acoustic energy
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US20070179587A1 (en) * 2006-01-30 2007-08-02 Xtent, Inc. Apparatus and methods for deployment of custom-length prostheses
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US20070196428A1 (en) * 2006-02-17 2007-08-23 Thierry Glauser Nitric oxide generating medical devices
US7601383B2 (en) * 2006-02-28 2009-10-13 Advanced Cardiovascular Systems, Inc. Coating construct containing poly (vinyl alcohol)
US7713637B2 (en) * 2006-03-03 2010-05-11 Advanced Cardiovascular Systems, Inc. Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer
AU2007227000A1 (en) 2006-03-20 2007-09-27 Xtent, Inc. Apparatus and methods for deployment of linked prosthetic segments
US20070231363A1 (en) * 2006-03-29 2007-10-04 Yung-Ming Chen Coatings formed from stimulus-sensitive material
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US20070259101A1 (en) * 2006-05-02 2007-11-08 Kleiner Lothar W Microporous coating on medical devices
US20070258903A1 (en) * 2006-05-02 2007-11-08 Kleiner Lothar W Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers
US8069814B2 (en) 2006-05-04 2011-12-06 Advanced Cardiovascular Systems, Inc. Stent support devices
US8304012B2 (en) * 2006-05-04 2012-11-06 Advanced Cardiovascular Systems, Inc. Method for drying a stent
US7985441B1 (en) 2006-05-04 2011-07-26 Yiwen Tang Purification of polymers for coating applications
US7775178B2 (en) * 2006-05-26 2010-08-17 Advanced Cardiovascular Systems, Inc. Stent coating apparatus and method
US9561351B2 (en) * 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US8568764B2 (en) * 2006-05-31 2013-10-29 Advanced Cardiovascular Systems, Inc. Methods of forming coating layers for medical devices utilizing flash vaporization
US20070281117A1 (en) * 2006-06-02 2007-12-06 Xtent, Inc. Use of plasma in formation of biodegradable stent coating
US8703167B2 (en) 2006-06-05 2014-04-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
US20070286882A1 (en) * 2006-06-09 2007-12-13 Yiwen Tang Solvent systems for coating medical devices
US8778376B2 (en) 2006-06-09 2014-07-15 Advanced Cardiovascular Systems, Inc. Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating
US8114150B2 (en) 2006-06-14 2012-02-14 Advanced Cardiovascular Systems, Inc. RGD peptide attached to bioabsorbable stents
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US8685430B1 (en) 2006-07-14 2014-04-01 Abbott Cardiovascular Systems Inc. Tailored aliphatic polyesters for stent coatings
US8952123B1 (en) 2006-08-02 2015-02-10 Abbott Cardiovascular Systems Inc. Dioxanone-based copolymers for implantable devices
WO2008017028A2 (en) 2006-08-02 2008-02-07 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US20080269865A1 (en) * 2006-08-07 2008-10-30 Xtent, Inc. Custom Length Stent Apparatus
DE102006038232A1 (en) * 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Endoprosthesis and method for producing such
US8703169B1 (en) 2006-08-15 2014-04-22 Abbott Cardiovascular Systems Inc. Implantable device having a coating comprising carrageenan and a biostable polymer
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
ATE517590T1 (en) 2006-09-15 2011-08-15 Boston Scient Ltd BIOLOGICALLY ERODABLE ENDOPROTHESES
CA2663220A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Medical devices and methods of making the same
WO2008034048A2 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprosthesis with biostable inorganic layers
JP2010503482A (en) 2006-09-18 2010-02-04 ボストン サイエンティフィック リミテッド Endoprosthesis
US8597673B2 (en) * 2006-12-13 2013-12-03 Advanced Cardiovascular Systems, Inc. Coating of fast absorption or dissolution
CA2674195A1 (en) 2006-12-28 2008-07-10 Boston Scientific Limited Bioerodible endoprostheses and methods of making same
US20080175882A1 (en) * 2007-01-23 2008-07-24 Trollsas Mikael O Polymers of aliphatic thioester
US20080199510A1 (en) 2007-02-20 2008-08-21 Xtent, Inc. Thermo-mechanically controlled implants and methods of use
CA2621452A1 (en) 2007-02-21 2008-08-21 Innovational Holdings, Llc Stent and method for reducing tissue damage after ischemic injury with thymosin b4
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8486132B2 (en) 2007-03-22 2013-07-16 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US8147769B1 (en) 2007-05-16 2012-04-03 Abbott Cardiovascular Systems Inc. Stent and delivery system with reduced chemical degradation
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
US10155881B2 (en) * 2007-05-30 2018-12-18 Abbott Cardiovascular Systems Inc. Substituted polycaprolactone for coating
US9737638B2 (en) * 2007-06-20 2017-08-22 Abbott Cardiovascular Systems, Inc. Polyester amide copolymers having free carboxylic acid pendant groups
US7927621B2 (en) * 2007-06-25 2011-04-19 Abbott Cardiovascular Systems Inc. Thioester-ester-amide copolymers
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
US8109904B1 (en) 2007-06-25 2012-02-07 Abbott Cardiovascular Systems Inc. Drug delivery medical devices
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
DE102007034364A1 (en) * 2007-07-24 2009-01-29 Biotronik Vi Patent Ag Degradable metal stent with active ingredient-containing coating
US20090041824A1 (en) * 2007-08-07 2009-02-12 Arsenal Medical, Inc. Method and apparatus for composite drug delivery medical devices
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US20090076591A1 (en) * 2007-09-19 2009-03-19 Boston Scientific Scimed, Inc. Stent Design Allowing Extended Release of Drug and/or Enhanced Adhesion of Polymer to OD Surface
US20090076584A1 (en) * 2007-09-19 2009-03-19 Xtent, Inc. Apparatus and methods for deployment of multiple custom-length prostheses
US9814553B1 (en) 2007-10-10 2017-11-14 Abbott Cardiovascular Systems Inc. Bioabsorbable semi-crystalline polymer for controlling release of drug from a coating
US20090104241A1 (en) * 2007-10-23 2009-04-23 Pacetti Stephen D Random amorphous terpolymer containing lactide and glycolide
US20090306120A1 (en) * 2007-10-23 2009-12-10 Florencia Lim Terpolymers containing lactide and glycolide
US20090110713A1 (en) * 2007-10-31 2009-04-30 Florencia Lim Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
US7833266B2 (en) 2007-11-28 2010-11-16 Boston Scientific Scimed, Inc. Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
WO2009099935A2 (en) * 2008-02-01 2009-08-13 Boston Scientific Scimed, Inc. Drug-coated medical devices for differential drug release
US9101503B2 (en) * 2008-03-06 2015-08-11 J.W. Medical Systems Ltd. Apparatus having variable strut length and methods of use
US8128983B2 (en) * 2008-04-11 2012-03-06 Abbott Cardiovascular Systems Inc. Coating comprising poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network
US20090297584A1 (en) * 2008-04-18 2009-12-03 Florencia Lim Biosoluble coating with linear over time mass loss
US20090285873A1 (en) * 2008-04-18 2009-11-19 Abbott Cardiovascular Systems Inc. Implantable medical devices and coatings therefor comprising block copolymers of poly(ethylene glycol) and a poly(lactide-glycolide)
US8916188B2 (en) * 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block
US9364349B2 (en) 2008-04-24 2016-06-14 Surmodics, Inc. Coating application system with shaped mandrel
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8697113B2 (en) * 2008-05-21 2014-04-15 Abbott Cardiovascular Systems Inc. Coating comprising a terpolymer comprising caprolactone and glycolide
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
WO2009155328A2 (en) 2008-06-18 2009-12-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20090319026A1 (en) * 2008-06-20 2009-12-24 Boston Scientific Scimed, Inc. Composite Stent with Reservoirs for Drug Delivery and Methods of Manufacturing
US7951193B2 (en) 2008-07-23 2011-05-31 Boston Scientific Scimed, Inc. Drug-eluting stent
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
WO2010027679A2 (en) * 2008-08-27 2010-03-11 Boston Scientific Scimed, Inc. Medical devices having coatings for therapeutic agent delivery
US11298252B2 (en) 2008-09-25 2022-04-12 Advanced Bifurcation Systems Inc. Stent alignment during treatment of a bifurcation
US8828071B2 (en) 2008-09-25 2014-09-09 Advanced Bifurcation Systems, Inc. Methods and systems for ostial stenting of a bifurcation
WO2010036982A1 (en) 2008-09-25 2010-04-01 Henry Bourang Partially crimped stent
US8821562B2 (en) 2008-09-25 2014-09-02 Advanced Bifurcation Systems, Inc. Partially crimped stent
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
EP2349080B1 (en) 2008-10-22 2016-04-13 Boston Scientific Scimed, Inc. Shape memory tubular stent with grooves
US20100106242A1 (en) * 2008-10-23 2010-04-29 Abbott Cardiovascular Systems Inc. Stent and method for making a stent
KR101668889B1 (en) * 2008-11-06 2016-10-24 바이오센서스 인터내셔널 그룹, 리미티드 Surface textured implants
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8697110B2 (en) * 2009-05-14 2014-04-15 Abbott Cardiovascular Systems Inc. Polymers comprising amorphous terpolymers and semicrystalline blocks
WO2011119573A1 (en) 2010-03-23 2011-09-29 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
CN103037815B (en) 2010-03-24 2015-05-13 高级分支系统股份有限公司 Methods and systems for treating a bifurcation with provisional side branch stenting
CA2794078A1 (en) 2010-03-24 2011-09-29 Advanced Bifurcation Systems, Inc. Stent alignment during treatment of a bifurcation
CN103037816B (en) 2010-03-24 2018-12-28 高级分支系统股份有限公司 System and method for handling furcation
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
US8632839B2 (en) * 2010-10-19 2014-01-21 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
KR101176956B1 (en) * 2011-02-01 2012-08-30 한국과학기술연구원 Stent with initial force and fabrication method thereof
EP2672932B1 (en) 2011-02-08 2018-09-19 Advanced Bifurcation Systems, Inc. System for treating a bifurcation with a fully crimped stent
WO2012109382A2 (en) 2011-02-08 2012-08-16 Advanced Bifurcation Systems, Inc. Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use
WO2012158530A1 (en) 2011-05-13 2012-11-22 Broncus Technologies, Inc. Methods and devices for ablation of tissue
US8709034B2 (en) 2011-05-13 2014-04-29 Broncus Medical Inc. Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
WO2013078235A1 (en) 2011-11-23 2013-05-30 Broncus Medical Inc Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
MX351261B (en) 2012-06-01 2017-10-06 Surmodics Inc Apparatus and method for coating balloon catheters.
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
US9283350B2 (en) 2012-12-07 2016-03-15 Surmodics, Inc. Coating apparatus and methods
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695857A (en) * 1990-12-24 1997-12-09 Westaim Technologies Inc. Actively sterile surfaces
US6096070A (en) * 1995-06-07 2000-08-01 Med Institute Inc. Coated implantable medical device
WO2001017577A1 (en) * 1999-09-03 2001-03-15 Advanced Cardiovascular Systems, Inc. A porous prosthesis and a method of depositing substances into the pores

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329383A (en) * 1979-07-24 1982-05-11 Nippon Zeon Co., Ltd. Non-thrombogenic material comprising substrate which has been reacted with heparin
US4606931A (en) * 1983-06-27 1986-08-19 International Business Machines Corporation Lift-off masking method
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4882168A (en) 1986-09-05 1989-11-21 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
JPH0696023B2 (en) * 1986-11-10 1994-11-30 宇部日東化成株式会社 Artificial blood vessel and method for producing the same
US5079600A (en) * 1987-03-06 1992-01-07 Schnur Joel M High resolution patterning on solid substrates
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4894231A (en) 1987-07-28 1990-01-16 Biomeasure, Inc. Therapeutic agent delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US5274074A (en) * 1987-12-17 1993-12-28 United States Surgical Corporation Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
JP2561309B2 (en) 1988-03-28 1996-12-04 テルモ株式会社 Medical material and manufacturing method thereof
US5328471A (en) 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US4977901A (en) 1988-11-23 1990-12-18 Minnesota Mining And Manufacturing Company Article having non-crosslinked crystallized polymer coatings
US5272012A (en) 1989-06-23 1993-12-21 C. R. Bard, Inc. Medical apparatus having protective, lubricious coating
US5971954A (en) 1990-01-10 1999-10-26 Rochester Medical Corporation Method of making catheter
CA2069644A1 (en) 1990-01-30 1991-07-31 Jan Feijen Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5298260A (en) * 1990-05-01 1994-03-29 Mediventures, Inc. Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality
US5300295A (en) * 1990-05-01 1994-04-05 Mediventures, Inc. Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH
US5306501A (en) * 1990-05-01 1994-04-26 Mediventures, Inc. Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers
WO1991017724A1 (en) * 1990-05-17 1991-11-28 Harbor Medical Devices, Inc. Medical device polymer
CA2081896A1 (en) * 1990-06-15 1991-12-16 James E. Shapland Drug delivery apparatus and method
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
US5112457A (en) 1990-07-23 1992-05-12 Case Western Reserve University Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants
US5455040A (en) 1990-07-26 1995-10-03 Case Western Reserve University Anticoagulant plasma polymer-modified substrate
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5244538A (en) * 1991-07-26 1993-09-14 Microelectronics And Computer Technology Corporation Method of patterning metal on a substrate using direct-write deposition of a mask
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
DE69325845T2 (en) * 1992-04-28 2000-01-05 Terumo Corp Thermoplastic polymer composition and medical devices made therefrom
EP0604022A1 (en) 1992-12-22 1994-06-29 Advanced Cardiovascular Systems, Inc. Multilayered biodegradable stent and method for its manufacture
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5824048A (en) * 1993-04-26 1998-10-20 Medtronic, Inc. Method for delivering a therapeutic substance to a body lumen
US20020055710A1 (en) 1998-04-30 2002-05-09 Ronald J. Tuch Medical device for delivering a therapeutic agent and method of preparation
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
EG20321A (en) 1993-07-21 1998-10-31 Otsuka Pharma Co Ltd Medical material and process for producing the same
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
WO1995010989A1 (en) * 1993-10-19 1995-04-27 Scimed Life Systems, Inc. Intravascular stent pump
US5723004A (en) 1993-10-21 1998-03-03 Corvita Corporation Expandable supportive endoluminal grafts
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5567410A (en) * 1994-06-24 1996-10-22 The General Hospital Corporation Composotions and methods for radiographic imaging
US5670558A (en) 1994-07-07 1997-09-23 Terumo Kabushiki Kaisha Medical instruments that exhibit surface lubricity when wetted
US5788979A (en) * 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
US5578073A (en) 1994-09-16 1996-11-26 Ramot Of Tel Aviv University Thromboresistant surface treatment for biomaterials
US5649977A (en) * 1994-09-22 1997-07-22 Advanced Cardiovascular Systems, Inc. Metal reinforced polymer stent
US5637113A (en) 1994-12-13 1997-06-10 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5569198A (en) * 1995-01-23 1996-10-29 Cortrak Medical Inc. Microporous catheter
US6017577A (en) 1995-02-01 2000-01-25 Schneider (Usa) Inc. Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices
US5919570A (en) 1995-02-01 1999-07-06 Schneider Inc. Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices
US5702754A (en) 1995-02-22 1997-12-30 Meadox Medicals, Inc. Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings
US5869127A (en) * 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US6231600B1 (en) * 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5605696A (en) 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US6120536A (en) 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
DE69624475T2 (en) * 1995-04-19 2003-05-28 Kazunori Kataoka HETEROTELECHELIC BLOCK COPOLYMERS AND METHOD FOR THE PRODUCTION THEREOF
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US6010530A (en) * 1995-06-07 2000-01-04 Boston Scientific Technology, Inc. Self-expanding endoluminal prosthesis
US5820917A (en) 1995-06-07 1998-10-13 Medtronic, Inc. Blood-contacting medical device and method
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US5667767A (en) 1995-07-27 1997-09-16 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5658995A (en) * 1995-11-27 1997-08-19 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
DK2111876T3 (en) 1995-12-18 2011-12-12 Angiodevice Internat Gmbh Crosslinked polymer preparations and methods for their use
US6033582A (en) * 1996-01-22 2000-03-07 Etex Corporation Surface modification of medical implants
US5713949A (en) * 1996-08-06 1998-02-03 Jayaraman; Swaminathan Microporous covered stents and method of coating
US5955509A (en) * 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
US5876433A (en) * 1996-05-29 1999-03-02 Ethicon, Inc. Stent and method of varying amounts of heparin coated thereon to control treatment
US5874165A (en) 1996-06-03 1999-02-23 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto polymeric subtrates
US5830178A (en) 1996-10-11 1998-11-03 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide
US6060518A (en) * 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
KR100215700B1 (en) * 1996-12-11 1999-08-16 김영환 Quantum wire structure of mutilayer compound semiconductor and method for forming the same
US5980972A (en) 1996-12-20 1999-11-09 Schneider (Usa) Inc Method of applying drug-release coatings
US5997517A (en) 1997-01-27 1999-12-07 Sts Biopolymers, Inc. Bonding layers for medical device surface coatings
US6240616B1 (en) * 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US5879697A (en) 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US6056993A (en) 1997-05-30 2000-05-02 Schneider (Usa) Inc. Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel
US6110483A (en) * 1997-06-23 2000-08-29 Sts Biopolymers, Inc. Adherent, flexible hydrogel and medicated coatings
US5980928A (en) 1997-07-29 1999-11-09 Terry; Paul B. Implant for preventing conjunctivitis in cattle
US5897911A (en) * 1997-08-11 1999-04-27 Advanced Cardiovascular Systems, Inc. Polymer-coated stent structure
US6121027A (en) 1997-08-15 2000-09-19 Surmodics, Inc. Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups
US6015541A (en) 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
US6110188A (en) 1998-03-09 2000-08-29 Corvascular, Inc. Anastomosis method
US6113629A (en) 1998-05-01 2000-09-05 Micrus Corporation Hydrogel for the therapeutic treatment of aneurysms
KR100314496B1 (en) * 1998-05-28 2001-11-22 윤동진 Non-thrombogenic heparin derivatives, process for preparation and use thereof
US6106889A (en) 1998-06-11 2000-08-22 Biocoat Incorporated Method of selective coating of articles
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
JP4898991B2 (en) 1998-08-20 2012-03-21 クック メディカル テクノロジーズ エルエルシー Sheathed medical device
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
US6335029B1 (en) * 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
WO2000012147A1 (en) 1998-09-02 2000-03-09 Scimed Life Systems, Inc. Drug delivery device for stent
US6206915B1 (en) * 1998-09-29 2001-03-27 Medtronic Ave, Inc. Drug storing and metering stent
US6419692B1 (en) * 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
AU4975500A (en) 1999-04-23 2000-11-10 Agion Technologies, Llc Stent having antimicrobial agent
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6283947B1 (en) * 1999-07-13 2001-09-04 Advanced Cardiovascular Systems, Inc. Local drug delivery injection catheter
US6494862B1 (en) 1999-07-13 2002-12-17 Advanced Cardiovascular Systems, Inc. Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway
US6287628B1 (en) * 1999-09-03 2001-09-11 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6379381B1 (en) * 1999-09-03 2002-04-30 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6503556B2 (en) * 2000-12-28 2003-01-07 Advanced Cardiovascular Systems, Inc. Methods of forming a coating for a prosthesis
US6503954B1 (en) * 2000-03-31 2003-01-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing actinomycin D and a method of forming the same
US6759054B2 (en) * 1999-09-03 2004-07-06 Advanced Cardiovascular Systems, Inc. Ethylene vinyl alcohol composition and coating
US6203551B1 (en) * 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6251136B1 (en) * 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6283949B1 (en) * 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US6527801B1 (en) * 2000-04-13 2003-03-04 Advanced Cardiovascular Systems, Inc. Biodegradable drug delivery material for stent
US6395326B1 (en) * 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US6585765B1 (en) * 2000-06-29 2003-07-01 Advanced Cardiovascular Systems, Inc. Implantable device having substances impregnated therein and a method of impregnating the same
US20020077693A1 (en) * 2000-12-19 2002-06-20 Barclay Bruce J. Covered, coiled drug delivery stent and method
US6555157B1 (en) * 2000-07-25 2003-04-29 Advanced Cardiovascular Systems, Inc. Method for coating an implantable device and system for performing the method
US6451373B1 (en) * 2000-08-04 2002-09-17 Advanced Cardiovascular Systems, Inc. Method of forming a therapeutic coating onto a surface of an implantable prosthesis
US6585926B1 (en) * 2000-08-31 2003-07-01 Advanced Cardiovascular Systems, Inc. Method of manufacturing a porous balloon
US6254632B1 (en) * 2000-09-28 2001-07-03 Advanced Cardiovascular Systems, Inc. Implantable medical device having protruding surface structures for drug delivery and cover attachment
US6506437B1 (en) * 2000-10-17 2003-01-14 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device having depots formed in a surface thereof
US6558733B1 (en) * 2000-10-26 2003-05-06 Advanced Cardiovascular Systems, Inc. Method for etching a micropatterned microdepot prosthesis
US6544543B1 (en) * 2000-12-27 2003-04-08 Advanced Cardiovascular Systems, Inc. Periodic constriction of vessels to treat ischemic tissue
US6540776B2 (en) * 2000-12-28 2003-04-01 Advanced Cardiovascular Systems, Inc. Sheath for a prosthesis and methods of forming the same
US6544223B1 (en) * 2001-01-05 2003-04-08 Advanced Cardiovascular Systems, Inc. Balloon catheter for delivering therapeutic agents
US6544582B1 (en) * 2001-01-05 2003-04-08 Advanced Cardiovascular Systems, Inc. Method and apparatus for coating an implantable device
US6605154B1 (en) * 2001-05-31 2003-08-12 Advanced Cardiovascular Systems, Inc. Stent mounting device
US6572644B1 (en) * 2001-06-27 2003-06-03 Advanced Cardiovascular Systems, Inc. Stent mounting device and a method of using the same to coat a stent
US6565659B1 (en) * 2001-06-28 2003-05-20 Advanced Cardiovascular Systems, Inc. Stent mounting assembly and a method of using the same to coat a stent
US6527863B1 (en) * 2001-06-29 2003-03-04 Advanced Cardiovascular Systems, Inc. Support device for a stent and a method of using the same to coat a stent
EP1273314A1 (en) 2001-07-06 2003-01-08 Terumo Kabushiki Kaisha Stent
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695857A (en) * 1990-12-24 1997-12-09 Westaim Technologies Inc. Actively sterile surfaces
US6096070A (en) * 1995-06-07 2000-08-01 Med Institute Inc. Coated implantable medical device
WO2001017577A1 (en) * 1999-09-03 2001-03-15 Advanced Cardiovascular Systems, Inc. A porous prosthesis and a method of depositing substances into the pores

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
DE102005021622B4 (en) * 2005-05-05 2014-11-20 Hemoteq Ag Full-surface coating of stents
DE102005021622A1 (en) * 2005-05-05 2006-11-16 Hemoteq Gmbh A method for coating the net or mesh fabric of surgically used blood vessel stents has a first thin coating applied to the web material and a second thicker coating applied to the webs and gaps
DE102005032604A1 (en) * 2005-07-13 2007-01-18 Gfe Medizintechnik Gmbh Absorbable, insertable into the body medical element, in particular resorbable implant
DE102006007231B4 (en) * 2006-02-15 2009-04-09 Acandis Gmbh & Co. Kg Method of wrapping a stent
DE102006007231A1 (en) * 2006-02-15 2007-08-30 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Method of wrapping a stent
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
DE102006038236A1 (en) * 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Biodegradable stent with an active coating
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese

Also Published As

Publication number Publication date
US6712845B2 (en) 2004-03-30
US20040073298A1 (en) 2004-04-15
US8110243B2 (en) 2012-02-07
US20080215141A1 (en) 2008-09-04
US20020155212A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
US6712845B2 (en) Coating for a stent and a method of forming the same
US6540776B2 (en) Sheath for a prosthesis and methods of forming the same
US6503556B2 (en) Methods of forming a coating for a prosthesis
US6713119B2 (en) Biocompatible coating for a prosthesis and a method of forming the same
US7396539B1 (en) Stent coatings with engineered drug release rate
US6733768B2 (en) Composition for coating an implantable prosthesis
US7901703B2 (en) Polycationic peptides for cardiovascular therapy
CA2501016C (en) Intraluminal prostheses and carbon dioxide-assisted methods of impregnating same with pharmacological agents
US6503954B1 (en) Biocompatible carrier containing actinomycin D and a method of forming the same
US6379381B1 (en) Porous prosthesis and a method of depositing substances into the pores
US6506437B1 (en) Methods of coating an implantable device having depots formed in a surface thereof
US6979347B1 (en) Implantable drug delivery prosthesis
US7384660B2 (en) Implantable device having substances impregnated therein and a method of impregnating the same
US7824729B2 (en) Methods for coating an implantable device

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP